8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Apr 29, 2026·SEC
Material company update
Apr 16, 2026·SEC
Autolus Therapeutics plc(AUTL)Earnings, Financials & Key Ratios
AUTL•NASDAQ
Price updated Jun 19, 2026
AboutAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.Show more
- Revenue$76M+646.7%
- EBITDA-$272M-16.2%
- Net Income-$288M-30.6%
- EPS (Diluted)-1.08-24.1%
- Gross Margin-27.83%+97.8%
- EBITDA Margin-359.43%+84.4%
- Operating Margin-372.45%+84.4%
- Net Margin-381.4%+82.5%
- ROE-95.2%-16.2%
AUTL Key Insights
Autolus Therapeutics plc (AUTL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 113.2%
✗Weaknesses
- ✗Profits declining 15.2% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AUTL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AUTL Price & Volume
Autolus Therapeutics plc (AUTL) stock price & volume — 10-year historical chart
Loading chart...
AUTL Growth Metrics
Autolus Therapeutics plc (AUTL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years95.19%
5 Years113.21%
3 Years130.21%
TTM927.51%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-22.47%
Return on Capital
10 Years-54.63%
5 Years-43.32%
3 Years-45.92%
Last Year-45.48%
AUTL Recent Earnings
Autolus Therapeutics plc (AUTL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 5/12 qtrs (56%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.27+6.9%
$0.29
Rev
$26M-0.2%
$26M
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.34-30.8%
$0.26
Rev
$24M+1.6%
$24M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.30-30.4%
$0.23
Rev
$21M-13.2%
$24M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.18+25.0%
$0.24
Rev
$21M-0.7%
$21M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.27vs $0.29+6.9% | $26Mvs $26M-0.2% |
| Q2 2026 | Mar 27, 2026 | $0.34vs $0.26-30.8% | $24Mvs $24M+1.6% |
| Q4 2025 | Nov 12, 2025 | $0.30vs $0.23-30.4% | $21Mvs $24M-13.2% |
| Q3 2025 | Aug 12, 2025 | $0.18vs $0.24+25.0% | $21Mvs $21M-0.7% |
Based on last 12 quarters of dataView full earnings history →
AUTL Peer Comparison
Autolus Therapeutics plc (AUTL) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 ALLO | 487.74M | 2.00 | -2.30 | -100% | -56.45% | 0.26 | ||
 CABA | 463.08M | 2.84 | -1.73 | -131.58% | 0.24 | |||
 LEGN | 5.17B | 27.93 | -17.46 | 64.04% | -21.97% | -24.91% | 0.41 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 |
Compare AUTL vs Peers
Autolus Therapeutics plc (AUTL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AUTL Income Statement
Autolus Therapeutics plc (AUTL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Sep'17 | Sep'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.69M | 1.05M | 2.91M | 1.72M | 1.51M | 6.19M | 1.7M | 10.12M | 75.56M | 92.59M |
Revenue Growth % | 39.69% | -38.26% | 178.19% | -41.02% | -12.13% | 311.02% | -72.59% | 496% | 646.68% | 927.51% |
Cost of Goods Sold | 1.01M | 48.3M | 105.42M | 134.89M | 0 | 0 | 0 | 141.02M | 96.59M | 102.95M |
COGS % of Revenue | 59.6% | 4620.4% | 3625.1% | 7865.19% | - | - | - | 1393.48% | 127.83% | - |
Gross Profit | 684K▲ 0% | -47.25M▼ 7008.4% | -102.51M▼ 116.9% | -133.17M▼ 29.9% | 1.51M▲ 101.1% | 6.19M▲ 311.0% | 1.7M▼ 72.6% | -130.9M▼ 7809.1% | -21.03M▲ 83.9% | -10.36M▲ 0% |
Gross Margin % | 40.4% | -4520.4% | -3525.1% | -7765.19% | 100% | 100% | 100% | -1293.48% | -27.83% | -11.19% |
Gross Profit Growth % | -6.81% | -7008.43% | -116.94% | -29.91% | 101.13% | 311.02% | -72.59% | -7809.07% | 83.93% | - |
Operating Expenses | 25.11M | 41.48M | 145.07M | 169.96M | 141.88M | 149.09M | 181.4M | 110.53M | 260.41M | 254.35M |
OpEx % of Revenue | 1483.22% | 3968.39% | 4988.65% | 9910.2% | 9414.8% | 2406.96% | 10683.1% | 1092.15% | 344.62% | - |
Selling, General & Admin | 9.1M | 16.85M | 39.45M | 34.97M | 31.86M | 31.9M | 46.74M | 0 | 131.82M | 142.24M |
SG&A % of Revenue | 537.45% | 1611.51% | 1356.67% | 2039.18% | 2114.47% | 515% | 2752.94% | - | 174.45% | - |
Research & Development | 16.01M | 24.64M | 105.62M | 134.99M | 110.84M | 117.35M | 130.48M | 158.14M | 128.59M | 112.11M |
R&D % of Revenue | 945.78% | 2356.89% | 3631.98% | 7871.02% | 7354.94% | 1894.64% | 7684.39% | 1562.61% | 170.17% | - |
Other Operating Expenses | -46K | 3.97M | 0 | 0 | -823K | -166K | 4.17M | -47.61M | 0 | 1 |
Operating Income | -23.42M▲ 0% | -57.53M▼ 145.7% | -247.58M▼ 330.3% | -303.13M▼ 22.4% | -140.37M▲ 53.7% | -142.89M▼ 1.8% | -179.7M▼ 25.8% | -241.43M▼ 34.3% | -281.44M▼ 16.6% | -264.71M▲ 0% |
Operating Margin % | -1383.22% | -5503.74% | -8513.76% | -17675.39% | -9314.8% | -2306.96% | -10583.1% | -2385.63% | -372.45% | -285.9% |
Operating Income Growth % | -62.9% | -145.68% | -330.33% | -22.44% | 53.69% | -1.79% | -25.76% | -34.35% | -16.57% | - |
EBITDA | -22.41M | -55.82M | -243.02M | -297.57M | -131.92M | -135.47M | -173.14M | -233.71M | -271.6M | -251.72M |
EBITDA Margin % | -1323.63% | -5340.26% | -8356.81% | -17350.79% | -8753.55% | -2187.13% | -10196.47% | -2309.39% | -359.43% | -271.86% |
EBITDA Growth % | -61.24% | -149.11% | -335.33% | -22.45% | 55.67% | -2.69% | -27.8% | -34.99% | -16.21% | 40.63% |
D&A (Non-Cash Add-back) | 1.01M | 1.71M | 4.56M | 5.57M | 8.46M | 7.42M | 6.57M | 7.72M | 9.84M | 13M |
EBIT | -23.42M | -52.03M | -141.96M | -168.15M | -140.93M | -139.66M | -163.34M | -240.79M | -281.44M | -261.16M |
Net Interest Income | 84K | 4.11M | 2.54M | 536K | -843K | -7.2M | -31.56M | 23.06M | -17.73M | -22.3M |
Interest Income | 84K | 4.12M | 2.54M | 536K | 262K | 1.71M | 13.51M | 32.35M | 19.02M | 22.14M |
Interest Expense | 0 | 12.67K | 0 | 0 | 1.1M | 8.9M | 45.07M | 9.29M | 36.76M | 44.43M |
Other Income/Expense | 38K | 6.91M | 138.89M | 136.88M | -1.66M | -5.67M | -28.7M | 22.29M | -15.41M | -23.51M |
Pretax Income | -23.38M▲ 0% | -36.33M▼ 55.4% | -108.69M▼ 199.2% | -166.26M▼ 53.0% | -142.04M▲ 14.6% | -148.57M▼ 4.6% | -208.4M▼ 40.3% | -219.13M▼ 5.1% | -296.85M▼ 35.5% | -288.22M▲ 0% |
Pretax Margin % | -1380.98% | -3475.09% | -3737.62% | -9694.29% | -9425.22% | -2398.56% | -12273.38% | -2165.36% | -392.84% | -311.29% |
Income Tax | -3.65M | -5.21M | 15.16M | -24.16M | 58K | 272K | -19K | 1.53M | -8.65M | 609.26K |
Effective Tax Rate % | 15.62% | 14.35% | -13.95% | 14.53% | -0.04% | -0.18% | 0.01% | -0.7% | 2.91% | -0.21% |
Net Income | -19.73M▲ 0% | -31.11M▼ 57.7% | -123.85M▼ 298.0% | -142.09M▼ 14.7% | -142.1M▼ 0.0% | -148.84M▼ 4.7% | -208.38M▼ 40.0% | -220.66M▼ 5.9% | -288.2M▼ 30.6% | -288.83M▲ 0% |
Net Margin % | -1165.21% | -2976.49% | -4258.91% | -8285.36% | -9429.06% | -2402.95% | -12272.26% | -2180.45% | -381.4% | -311.95% |
Net Income Growth % | -57.19% | -57.73% | -298.04% | -14.73% | -0% | -4.75% | -40.01% | -5.89% | -30.61% | -21.29% |
Net Income (Continuing) | -19.73M | -44.75M | -123.85M | -142.09M | -142.1M | -148.84M | -208.38M | -220.66M | -288.2M | -288.83M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.43▲ 0% | -0.99▲ 30.8% | -2.88▼ 190.9% | -2.76▲ 4.2% | -1.97▲ 28.6% | -1.57▲ 20.3% | -1.20▲ 23.6% | -0.87▲ 27.5% | -1.08▼ 24.1% | -1.09▲ 0% |
EPS Growth % | -57.14% | 30.77% | -190.91% | 4.17% | 28.62% | 20.3% | 23.57% | 27.5% | -24.14% | -22.47% |
EPS (Basic) | -1.43 | -0.99 | -2.88 | -2.76 | -1.97 | -1.57 | -1.20 | -0.87 | -1.08 | - |
Diluted Shares Outstanding | 13.78M | 31.56M | 43.07M | 51.56M | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M | 266.14M |
Basic Shares Outstanding | 13.78M | 31.56M | 43.07M | 51.56M | 72.08M | 94.99M | 173.94M | 255.16M | 266.14M | 266.14M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AUTL Balance Sheet
Autolus Therapeutics plc (AUTL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Sep'17 | Sep'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 142.48M | 199.14M | 249.26M | 193.98M | 346.95M | 425.77M | 275.3M | 660.93M | 435.92M | 368.83M |
Cash & Short-Term Investments | 137.07M | 189.3M | 211.43M | 154.09M | 310.34M | 382.44M | 239.57M | 588.02M | 300.71M | 229.43M |
Cash Only | 137.07M | 189.3M | 211.43M | 154.09M | 310.34M | 382.44M | 239.57M | 227.38M | 104.13M | 130.93M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 360.64M | 196.58M | 98.51M |
Accounts Receivable | 4.73M | 9.26M | 30.52M | 29.68M | 68K | 28.98M | 1.05M | 48.24M | 75.26M | 27.66M |
Days Sales Outstanding | 1.02K | 3.23K | 3.83K | 6.32K | 16.47 | 1.71K | 225.06 | 1.74K | 363.53 | 268.93 |
Inventory | 0 | 2.21M | 0 | 0 | 0 | 0 | 0 | 4.14M | 33.21M | 33.23M |
Days Inventory Outstanding | - | 16.69 | - | - | - | - | - | 10.71 | 125.49 | 104.69 |
Other Current Assets | 0 | 717K | 279K | 0 | 27.83M | 2.02M | 26.05M | 5.32M | 26.74M | 78.5M |
Total Non-Current Assets | 6.18M | 18.51M | 54.28M | 100.26M | 58.61M | 64.5M | 100.08M | 121.8M | 153.15M | 158.23M |
Property, Plant & Equipment | 6.18M | 9.22M | 51.57M | 89.68M | 52.32M | 58.42M | 95.65M | 105.05M | 128.5M | 134.47M |
Fixed Asset Turnover | 0.27x | 0.11x | 0.06x | 0.02x | 0.03x | 0.11x | 0.02x | 0.10x | 0.59x | 0.72x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 9.29M | 254K | 158K | 65K | 0 | 0 | 12.37M | 19.81M | 18.98M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 2.04M | 8.67M | 6.23M | 4.01M | 1.36M | 1.13M | 1.28M | 1.21M |
Total Assets | 148.66M▲ 0% | 217.66M▲ 46.4% | 303.53M▲ 39.5% | 294.24M▼ 3.1% | 405.56M▲ 37.8% | 490.27M▲ 20.9% | 375.38M▼ 23.4% | 782.73M▲ 108.5% | 589.07M▼ 24.7% | 527.07M▲ 0% |
Asset Turnover | 0.01x | 0.00x | 0.01x | 0.01x | 0.00x | 0.01x | 0.00x | 0.01x | 0.13x | 0.15x |
Asset Growth % | 334.94% | 46.41% | 39.45% | -3.06% | 37.83% | 20.89% | -23.43% | 108.51% | -24.74% | -89.67% |
Total Current Liabilities | 5.03M | 12.52M | 24.98M | 33.63M | 28.55M | 46.37M | 44.74M | 60.74M | 73.44M | 63.6M |
Accounts Payable | 1.95M | 3.04M | 0 | 2.26M | 431K | 531K | 103K | 1.97M | 3.08M | 1.87M |
Days Payables Outstanding | 703.95 | 22.94 | - | 6.12 | - | - | - | 5.1 | 11.65 | 18.91 |
Short-Term Debt | 0 | 0 | 2.51M | 3.59M | 0 | 0 | 0 | 0 | 14.56M | 3.06M |
Deferred Revenue (Current) | 197K | 569K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.71M |
Other Current Liabilities | 589K | 11.03M | 15.51M | 19.05M | 160K | 10.57M | 15.29M | 23.66M | 55.79M | 58.67M |
Current Ratio | 28.31x | 15.91x | 9.98x | 5.77x | 12.15x | 9.18x | 6.15x | 10.88x | 5.94x | 5.80x |
Quick Ratio | 28.31x | 15.73x | 9.98x | 5.77x | 12.15x | 9.18x | 6.15x | 10.81x | 5.48x | 5.28x |
Cash Conversion Cycle | - | 3.23K | - | - | - | - | - | 1.75K | 477.37 | 354.71 |
Total Non-Current Liabilities | 1.03M | 601K | 23.71M | 50.57M | 63.69M | 145.23M | 219.17M | 294.66M | 337.5M | 354.64M |
Long-Term Debt | 0 | 221K | 0 | 0 | 47.02M | 0 | 0 | 0 | 270.2M | 76.89M |
Capital Lease Obligations | 265K | 221K | 23.71M | 50.57M | 16.55M | 19.22M | 47.91M | 49.63M | 66.82M | 189.09M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 763K | 159K | 0 | 0 | 128K | 126.02M | 171.26M | 245.03M | 477K | 277.75M |
Total Liabilities | 6.06M | 12.52M | 48.69M | 84.2M | 92.24M | 191.6M | 263.91M | 355.4M | 410.94M | 418.24M |
Total Debt | 265K | 221K | 26.22M | 54.16M | 68.01M | 24.26M | 52.97M | 52.63M | 351.59M | 79.96M |
Net Debt | -136.81M | -189.08M | -185.21M | -99.92M | -242.32M | -358.18M | -186.6M | -174.75M | 247.45M | -50.97M |
Debt / Equity | 0.00x | 0.00x | 0.10x | 0.26x | 0.22x | 0.08x | 0.48x | 0.12x | 1.97x | 0.73x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.32x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.20x |
Interest Coverage | - | -4107.60x | - | - | -127.54x | -15.68x | -3.62x | -25.91x | -7.66x | -5.88x |
Total Equity | 142.6M▲ 0% | 205.14M▲ 43.9% | 254.84M▲ 24.2% | 210.03M▼ 17.6% | 313.32M▲ 49.2% | 298.67M▼ 4.7% | 111.47M▼ 62.7% | 427.32M▲ 283.3% | 178.13M▼ 58.3% | 108.83M▲ 0% |
Equity Growth % | 364.7% | 43.86% | 24.23% | -17.58% | 49.18% | -4.67% | -62.68% | 283.34% | -58.32% | -207.7% |
Book Value per Share | 10.35 | 6.50 | 5.92 | 4.07 | 4.35 | 3.14 | 0.64 | 1.67 | 0.67 | 0.41 |
Total Shareholders' Equity | 142.6M | 205.14M | 254.84M | 210.03M | 313.32M | 298.67M | 111.47M | 427.32M | 178.13M | 108.83M |
Common Stock | 1K | 1.28K | 120K | 121K | 4K | 8K | 8K | 12K | 12K | 12K |
Retained Earnings | -47.9M | 163.84M | -237.15M | -379.24M | -521.34M | -670.18M | -878.56M | -1.1B | -1.39B | -1.46B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -3.85M | -76.27M | -8.69M | -5.86M | -8.45M | -38.9M | -28.99M | -29.17M | -5.36M | -6.63M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AUTL Cash Flow Statement
Autolus Therapeutics plc (AUTL) cash flow — operating, investing & free cash flow history
| Metric | Sep'17 | Sep'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -16.36M | -25.85M | -101.48M | -117.76M | -117.86M | -112.31M | -145.59M | -206.27M | -283.57M | -273.32M |
Operating CF Margin % | -966.33% | -2472.62% | -3489.82% | -6866.36% | -7820.9% | -1813.17% | -8574.03% | -2038.25% | -375.27% | - |
Operating CF Growth % | -66.11% | -57.99% | -292.63% | -16.04% | -0.09% | 4.71% | -29.63% | -41.68% | -37.47% | -94.87% |
Net Income | -19.73M | -31.11M | -123.85M | -142.09M | -142.1M | -148.84M | -208.38M | -220.66M | -287.53M | -288.83M |
Depreciation & Amortization | 1.01M | 1.1M | 4.61M | 5.66M | 8.46M | 7.42M | 6.57M | 7.72M | 9.81M | 12.18M |
Stock-Based Compensation | 3.15M | 5.03M | 30.21M | 20.11M | 9.94M | 12.01M | 11.2M | 15.47M | 14.44M | 15.14M |
Deferred Taxes | 0 | -5.21M | -399K | -1.34M | -72K | -268K | -986K | -185K | -286K | -789K |
Other Non-Cash Items | 5.17M | -1.07M | 4.14M | -1.5M | 1.77M | 13.39M | 45.72M | 15.04M | 32.1M | -13.16M |
Working Capital Changes | -795K | 5.42M | -16.2M | 1.41M | 4.14M | 3.97M | 292K | -23.66M | -52.11M | 2.27M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -24.21M | -13.46M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.23M | -40.34M | 15.14M |
Change in Payables | 434K | 8.65M | -1.45M | 1.44M | -1.82M | 22K | -509K | 1.59M | 1.3M | -1.74M |
Cash from Investing | -2.88M | -7.65M | -18.67M | -14.68M | -8.86M | -10.84M | -10.99M | -394.55M | 158.46M | 314.16M |
Capital Expenditures | -2.88M | -8.77M | -18.34M | -14.68M | -8.86M | -10.84M | -10.99M | -22.07M | 0 | -15.52M |
CapEx % of Revenue | 169.88% | 839.09% | 630.71% | 856.03% | 587.72% | 175.02% | 647% | 218.13% | 25.26% | 16.76% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 1.13M | -327K | 0 | 0 | 0 | 0 | -12.74M | -27.13M | -6.06M |
Cash from Financing | 127.69M | 117.49M | 108.86M | 74.42M | 284.06M | 223.61M | -883K | 589.55M | -4.34M | -6.4M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.06M |
Equity Issued (Net) | 127.69M | 156.92M | 224.78M | 154.16M | 245.9M | 163.85M | 0 | 549.98M | 0 | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -3.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -115.92M | -79.75M | 38.16M | 59.76M | -883K | 39.58M | -4.34M | -4.34M |
Net Change in Cash | 109.01M▲ 0% | 86.98M▼ 20.2% | -6.13M▼ 107.0% | -57.34M▼ 836.2% | 156.59M▲ 373.1% | 72.08M▼ 54.0% | -142.43M▼ 297.6% | -11.53M▲ 91.9% | -123.17M▼ 968.3% | 35.17M▲ 0% |
Free Cash Flow | -19.24M▲ 0% | -34.62M▼ 80.0% | -120.15M▼ 247.1% | -132.44M▼ 10.2% | -126.72M▲ 4.3% | -123.15M▲ 2.8% | -156.57M▼ 27.1% | -241.09M▼ 54.0% | -303.32M▼ 25.8% | -291.52M▲ 0% |
FCF Margin % | -1136.21% | -3311.71% | -4131.77% | -7722.39% | -8408.63% | -1988.2% | -9221.02% | -2382.31% | -401.4% | -314.86% |
FCF Growth % | -64.35% | -79.97% | -247.07% | -10.23% | 4.32% | 2.82% | -27.14% | -53.98% | -25.81% | -2.7% |
FCF per Share | -1.40 | -1.10 | -2.79 | -2.57 | -1.76 | -1.30 | -0.90 | -0.94 | -1.14 | -1.10 |
FCF Conversion (FCF/Net Income) | 0.83x | 0.83x | 0.82x | 0.83x | 0.83x | 0.75x | 0.70x | 0.93x | 0.98x | 1.01x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 1.53M | 1.84M | 364K | 471K | 551K | 2.39M | 0 | 1.03M |
AUTL Key Ratios
Autolus Therapeutics plc (AUTL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -22.77% | -17.9% | -53.85% | -61.13% | -54.3% | -48.64% | -101.61% | -81.91% | -95.2% | -128.53% |
Return on Invested Capital (ROIC) | -407.88% | -394.78% | -433.37% | -252.98% | -116.27% | -1865.44% | - | -204.08% | -62.25% | -78.18% |
Gross Margin | 40.4% | -4520.4% | -3525.1% | -7765.19% | 100% | 100% | 100% | -1293.48% | -27.83% | -11.19% |
Net Margin | -1165.21% | -2976.49% | -4258.91% | -8285.36% | -9429.06% | -2402.95% | -12272.26% | -2180.45% | -381.4% | -311.95% |
Debt / Equity | 0.00x | 0.00x | 0.10x | 0.26x | 0.22x | 0.08x | 0.48x | 0.12x | 1.97x | 0.73x |
Interest Coverage | - | -4107.60x | - | - | -127.54x | -15.68x | -3.62x | -25.91x | -7.66x | -5.88x |
FCF Conversion | 0.83x | 0.83x | 0.82x | 0.83x | 0.83x | 0.75x | 0.70x | 0.93x | 0.98x | 1.01x |
Revenue Growth | 39.69% | -38.26% | 178.19% | -41.02% | -12.13% | 311.02% | -72.59% | 496% | 646.68% | 927.51% |
Related:AUTL Dividend History·AUTL Revenue History·AUTL Price History·AUTL P/E History·AUTL Financial Ratios·AUTL Institutional Holders
AUTL SEC Filings & Documents
Autolus Therapeutics plc (AUTL) SEC filings — annual & quarterly reports (10-K, 10-Q)
AUTL Frequently Asked Questions
Autolus Therapeutics plc (AUTL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Autolus Therapeutics plc (AUTL) reported $92.6M in revenue for fiscal year 2025. This represents a 98282% increase from $0.1M in 2015.
Autolus Therapeutics plc (AUTL) grew revenue by 646.7% over the past year. This is strong growth.
Autolus Therapeutics plc (AUTL) reported a net loss of $288.8M for fiscal year 2025.
Dividend & Returns
Autolus Therapeutics plc (AUTL) has a return on equity (ROE) of -95.2%. Negative ROE indicates the company is unprofitable.
Autolus Therapeutics plc (AUTL) had negative free cash flow of $291.5M in fiscal year 2025, likely due to heavy capital investments.